Cargando…
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
Cangrelor is the only currently available intravenous platelet P2Y(12) receptor inhibitor. It is characterized by potent, predictable, and rapidly reversible antiplatelet effects. Cangrelor has been tested in the large CHAMPION (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Plat...
Autores principales: | De Luca, Leonardo, Steg, Philippe Gabriel, Bhatt, Deepak L., Capodanno, Davide, Angiolillo, Dominick J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403274/ https://www.ncbi.nlm.nih.gov/pubmed/34212768 http://dx.doi.org/10.1161/JAHA.121.022125 |
Ejemplares similares
-
Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
por: Ortega‐Paz, Luis, et al.
Publicado: (2021) -
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor
inhibitors and cangrelor) in percutaneous coronary intervention: from
pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019) -
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
por: Claessen, Bimmer E., et al.
Publicado: (2020) -
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
por: Jensen, Ivar S., et al.
Publicado: (2021) -
Our Contemporaries
Publicado: (1917)